Hyderabad based pharma company Suven Life Sciences has reported a 7.8% increase in its standalone net profits, which rose to Rs. 40.06 crore in the Q4 ended March 2017, up from Rs 37.2 crore in the same period last year. Net sales of the firm were up 3.3% to Rs. 174.99 crore in the quarter.

Suven Life Sciences, which has been granted product patents in international markets for treatments of neurogenerative diseases, said it remained optimistic about growth for the coming FY18 quarter, and said its board has declared and paid an interim dividend of Re1 per share for FY17. The company reported a consolidated net profit for the entire FY of Rs 87.18 crore, compared to Rs 71.8 crore in the previous year. Suven's share price has been trending above all its SMAs in the week before results.